Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAY 987516 is an experimental sunscreen formulation developed by Bayer, intended for topical application to provide protection against ultraviolet (UV) radiation. It has been evaluated in clinical studies for its Sun Protection Factor (SPF) and UVA Protection Factor (UVAPF) efficacy, specifically measuring its ability to prevent minimal persistent pigment-darkening doses on human skin. Additionally, safety assessments have been conducted to evaluate its potential for eye stinging and its suitability for use during outdoor sports. The formulation exists in several experimental variants identified by internal codes such as Y65-110 and X15-158, often formulated to provide SPF 50 protection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BAY 987516.